Charité-Universitätsmedizin Berlin, Experimental and Clinical Research Center - ECRC, Berlin, Germany; Charité-Universitätsmedizin Berlin, Institute of Neuropathology, Berlin, Germany.
Piramal Imaging GmbH, Berlin, Germany.
Psychiatry Res Neuroimaging. 2017 Jul 30;265:98-101. doi: 10.1016/j.pscychresns.2016.10.011. Epub 2016 Nov 5.
Today, the use of biomarkers such as amyloid-specific positron emission tomography (PET) tracers and information derived from cerebrospinal fluid (CSF) can support the diagnosis of Alzheimer's disease (AD) as an indicator for the presence of amyloid pathology. We here show that the PET signal of the F-labelled tracer florbetaben (NeuraCeq™), that binds to amyloid-beta plaques, inversely correlates with CSF levels of Aß42, another biomarker for AD. Results from the two biomarkers were concordant in 35 out of 38 subjects. In 7 AD subjects (20%) at least one biomarker was inconsistent with the clinical diagnosis. This confirms known limitations of the clinical AD diagnosis and highlights the potential of biomarker-assisted diagnosis to improve accuracy.
如今，使用生物标志物（如淀粉样蛋白特异性正电子发射断层扫描 [PET] 示踪剂）以及来自脑脊液（CSF）的信息可以支持阿尔茨海默病（AD）的诊断，作为淀粉样蛋白病理存在的指标。我们在此表明，与淀粉样蛋白-β斑块结合的 F 标记示踪剂 florbetaben（NeuraCeq™）的 PET 信号与 CSF 中 Aβ42 水平呈负相关，Aβ42 也是 AD 的另一个生物标志物。在 38 名受试者中，有 35 名受试者的两种生物标志物结果一致。在 7 名 AD 受试者（20%）中，至少有一种生物标志物与临床诊断不一致。这证实了已知的 AD 临床诊断的局限性，并强调了生物标志物辅助诊断提高准确性的潜力。
